IL311863A - Combinations of KRAS G12D inhibitors and irinotecan and therapeutic methods - Google Patents

Combinations of KRAS G12D inhibitors and irinotecan and therapeutic methods

Info

Publication number
IL311863A
IL311863A IL311863A IL31186324A IL311863A IL 311863 A IL311863 A IL 311863A IL 311863 A IL311863 A IL 311863A IL 31186324 A IL31186324 A IL 31186324A IL 311863 A IL311863 A IL 311863A
Authority
IL
Israel
Prior art keywords
combination
kras
inhibitor
carcinoma
irinotecan
Prior art date
Application number
IL311863A
Other languages
English (en)
Hebrew (he)
Inventor
Jill Hallin
James Gail Christensen
Vickie Bowcut
Peter Olson
Original Assignee
Mirati Therapeutics Inc
Jill Hallin
James Gail Christensen
Vickie Bowcut
Peter Olson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc, Jill Hallin, James Gail Christensen, Vickie Bowcut, Peter Olson filed Critical Mirati Therapeutics Inc
Publication of IL311863A publication Critical patent/IL311863A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL311863A 2021-10-05 2022-10-04 Combinations of KRAS G12D inhibitors and irinotecan and therapeutic methods IL311863A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163252405P 2021-10-05 2021-10-05
PCT/US2022/045625 WO2023059600A1 (en) 2021-10-05 2022-10-04 Combinations of kras g12d inhibitors with irinotecan and related methods of treatment

Publications (1)

Publication Number Publication Date
IL311863A true IL311863A (en) 2024-06-01

Family

ID=85803676

Family Applications (1)

Application Number Title Priority Date Filing Date
IL311863A IL311863A (en) 2021-10-05 2022-10-04 Combinations of KRAS G12D inhibitors and irinotecan and therapeutic methods

Country Status (10)

Country Link
US (1) US20250249003A1 (https=)
EP (1) EP4412720A4 (https=)
JP (1) JP2024537137A (https=)
KR (1) KR20240073115A (https=)
CN (1) CN118354794A (https=)
AU (1) AU2022361219A1 (https=)
CA (1) CA3233571A1 (https=)
IL (1) IL311863A (https=)
MX (1) MX2024004214A (https=)
WO (1) WO2023059600A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250114339A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2017172678A1 (en) 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
MX2022002465A (es) 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation

Also Published As

Publication number Publication date
KR20240073115A (ko) 2024-05-24
CA3233571A1 (en) 2023-04-13
JP2024537137A (ja) 2024-10-10
EP4412720A1 (en) 2024-08-14
WO2023059600A1 (en) 2023-04-13
MX2024004214A (es) 2024-07-29
EP4412720A4 (en) 2025-08-13
CN118354794A (zh) 2024-07-16
US20250249003A1 (en) 2025-08-07
AU2022361219A1 (en) 2024-04-11

Similar Documents

Publication Publication Date Title
IL311834A (en) Combinations of KRAS G12D inhibitors with PI3KA inhibitors and therapeutic methods
IL311863A (en) Combinations of KRAS G12D inhibitors and irinotecan and therapeutic methods
IL274601B2 (en) Kras g12c inhibitors
FI3849537T3 (fi) Yhdistelmäterapioita
JP2025000632A5 (https=)
JP2025000629A5 (https=)
JP2025000630A5 (https=)
IL315645A (en) Combination therapies comprising a sos1 inhibitor and an egfr inhibitor
CA2758300C (en) Checkpoint kinase 1 inhibitors for potentiating dna damaging agents
JP2022548791A5 (https=)
IL314486A (en) Quinazoline compounds inhibit PAN-KRAS
EP3110509B1 (en) Treating cancer with a combination comprising dinaciclib
JP2024537140A5 (https=)
US8481557B2 (en) Method of treatment using checkpoint kinase 1 inhibitors
JP2024537137A5 (https=)
JP2025512999A5 (https=)
IL315648A (en) Combination therapy of SOS1 inhibitor and MEK inhibitor
US20110034498A1 (en) Dosing regimens for the treatment of cancer
IL319808A (en) Combined treatments
CN120693331A (zh) 2-(4-(4-(氨基甲基)-1-氧代-1,2-二氢酞嗪-6-基)-1-甲基-1h-吡唑-5-基)-4-氯-6-环丙氧基-3-氟苄腈的晶形
WO2023019095A2 (en) Momelotinib combination therapy
JP2025513802A5 (https=)
KR20250143121A (ko) 2-(4-(4-(아미노메틸)-1-옥소-1,2-디히드로프탈라진-6-일)-1-메틸-1h-피라졸-5-일)-4-클로로-6-시클로프로폭시-3-플루오로벤조니트릴의결정질 형태
AU2023343307A1 (en) Physical forms of an inhibitor of prc2
RU2025120876A (ru) Соединения, ингибирующие Prmt5, и их применение